Download Free Neuropsychopharmacology And Therapeutics Book in PDF and EPUB Free Download. You can read online Neuropsychopharmacology And Therapeutics and write the review.

Neuropsychopharmacology is a relatively new subject area in the neurosciences. It is a field of study that describes the effects of drugs from the molecular to the behavioural level and requires integration and synthesis of knowledge from various disciplines including neuroanatomy, physiology, molecular biology, pharmacology and the behavioural sciences. The principal aims of this book are to provide students with a clear understanding of CNS disorders, and an appreciation of how basic and clinical research findings can be translated into therapeutics. After an introduction to the subject area, the remaining chapters are focused on reviewing the main psychiatric and neurological disorders that are covered in most courses. They are discussed in terms of their clinical symptoms, epidemiology, pathology, aetiology, underlying neurobiological and neurochemical mechanisms, pharmacotherapy, adjunctive non-pharmacological treatments, and clinical outcomes. Each chapter of the book is a ‘stand-alone’ chapter and is written in a clear, accessible style. Written by an author with many years teaching and research experience, this textbook will prove invaluable for students of pharmacology, pharmacy and the medical sciences needing a truly integrated introduction to this exciting field.
The text ranges from drugs that affect the mood and behavior to hypnotics, narcotics, anticonvulsants, and analgesics, as well as a variety of drugs that affect the autonomic nervous system and psychoactive drugs used for non-medical reasons - nicotine, alcohol, opiates, psychostimulants and cannabis."--BOOK JACKET.
Thoroughly updated and completely reorganized for a sharper clinical focus, the Fifth Edition of this world-renowned classic synthesizes the latest advances in basic neurobiology, biological psychiatry, and clinical neuropsychopharmacology. The book establishes a critical bridge connecting new discoveries in molecular and cellular biology, genetics, and neuroimaging with the etiology, diagnosis, and treatment of all neuropsychiatric disorders. Nine sections focus on specific groups of disorders, covering clinical course, genetics, neurobiology, neuroimaging, and current and emerging therapeutics. Four sections cover neurotransmitter and signal transduction, emerging methods in molecular biology and genetics, emerging imaging technologies and their psychiatric applications, and drug discovery and evaluation. Compatibility: BlackBerry(R) OS 4.1 or Higher / iPhone/iPod Touch 2.0 or Higher /Palm OS 3.5 or higher / Palm Pre Classic / Symbian S60, 3rd edition (Nokia) / Windows Mobile(TM) Pocket PC (all versions) / Windows Mobile Smartphone / Windows 98SE/2000/ME/XP/Vista/Tablet PC
This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.
This is a spin-off from Stephen M. Stahl's new, completely revised and updated version of his much-acclaimed Prescriber's Guide, covering drugs to treat depression.
With recent studies using genetic, epigenetic, and other molecular and neurochemical approaches, a new era has begun in understanding pathophysiology of suicide. Emerging evidence suggests that neurobiological factors are not only critical in providing potential risk factors but also provide a promising approach to develop more effective treatment and prevention strategies. The Neurobiological Basis of Suicide discusses the most recent findings in suicide neurobiology. Psychological, psychosocial, and cultural factors are important in determining the risk factors for suicide; however, they offer weak prediction and can be of little clinical use. Interestingly, cognitive characteristics are different among depressed suicidal and depressed nonsuicidal subjects, and could be involved in the development of suicidal behavior. The characterization of the neurobiological basis of suicide is in delineating the risk factors associated with suicide. The Neurobiological Basis of Suicide focuses on how and why these neurobiological factors are crucial in the pathogenic mechanisms of suicidal behavior and how these findings can be transformed into potential therapeutic applications.
Nervous system diseases and disorders are highly prevalent and substantially contribute to the overall disease burden. Despite significant information provided by the use of animal models in the understanding of the biology of nervous system disorders and the development of therapeutics; limitations have also been identified. Treatment options that are high in efficacy and low in side effects are still lacking for many diseases and, in some cases are nonexistent. A particular problem in drug development is the high rate of attrition in Phase II and III clinical trials. Why do many therapeutics show promise in preclinical animal models but then fail to elicit predicted effects when tested in humans? On March 28 and 29, 2012, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened the workshop "Improving Translation of Animal Models for Nervous System Disorders" to discuss potential opportunities for maximizing the translation of new therapies from animal models to clinical practice. The primary focus of the workshop was to examine mechanisms for increasing the efficiency of translational neuroscience research through discussions about how and when to use animal models most effectively and then best approaches for the interpretation of the data collected. Specifically, the workshop objectives were to: discuss key issues that contribute to poor translation of animal models in nervous system disorders, examine case studies that highlight successes and failures in the development and application of animal models, consider strategies to increase the scientific rigor of preclinical efficacy testing, explore the benefits and challenges to developing standardized animal and behavioral models. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary also identifies methods to facilitate development of corresponding animal and clinical endpoints, indentifies methods that would maximize bidirectional translation between basic and clinical research and determines the next steps that will be critical for improvement of the development and testing of animal models of disorders of the nervous system.